Monday, December 23, 2024
HomeTagsNeurodegenerative conditions

neurodegenerative conditions

Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, announced that the New Zealand Medicines...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics